Overweight and obesity accelerate the progression of IgA nephropathy: Prognostic utility of a combination of BMI and histopathological parameters

Clinical and Experimental Nephrology

Volumn 16, Issue 5, 2012, Pages 706-712

  Kataoka, Hiroshi ^a   Ohara, Mamiko ^b   Shibui, Kaori ^b   Sato, Masayo ^a   Suzuki, Tomo ^c   Amemiya, Nobuyuki ^a   Watanabe, Yoshihiko ^b   Honda, Kazuho ^a   Mochizuki, Takahiro ^b   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b KAMEDA MEDICAL CENTER   (Japan)

^c SAKURA NATIONAL HOSPITAL   (Japan)

Author keywords

BMI; Glomerular enlargement; IgA nephropathy; Obesity; Outcomes; The Oxford classification

Indexed keywords

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CLASSIFICATION; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; GLOMERULUS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; MALE; MAXIMAL GLOMERULAR AREA; MESANGIAL HYPERCELLULARITY; MESANGIUM; OBESITY; OXFORD PATHOLOGICAL CLASSIFICATION; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RENAL SYSTEM PARAMETERS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; BODY MASS INDEX; CREATININE; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84868343865     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0613-7     Document Type: Article

References (29)

1. Nenov VD, Taal MW, Sakharova OV, Brenner BM. Multi-hit nature of chronic renal disease. Curr Opin Nephrol Hypertens. 2000;9:85-97.
2. Taal MW, Brenner BM. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int. 2006;70:1694-705.
3. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005;16:2088-97.
4. Berthoux FC, Mohey H, Afiani A. Natural history of primary IgA nephropathy. Semin Nephrol. 2008;28:4-9.
5. Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant. 2002;17:1197-203.
6. Goto M, Kawamura T, Wakai K, Ando M, Endoh M, Tomino Y. Risk stratification for progression of IgA nephropathy using a decision tree induction algorithm. Nephrol Dial Transplant. 2009;24:1242-7.
7. Glassock RJ. IgA nephropathy: challenges and opportunities. Cleve Clin J Med. 2008;75:569-76.
8. Roufosse CA, Cook HT. Pathological predictors of prognosis in immunoglobulin A nephropathy: a review. Curr Opin Nephrol Hypertens. 2009;18:212-9.
9. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73:19-33.
10. Liu H, Shi H, Yu J, Chen F, Jiang Q, Hu D. Obesity and chronic kidney disease in patients with chronic heart failure: an insight from the China Heart Survey. Clin Exp Nephrol. 2011;15:522-8.
11. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21-8.
12. Zoccali C. The obesity epidemics in ESRD: from wasting to waist? Nephrol Dial Tranplant. 2009;24:376-80.
13. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870-6.
14. Kato S, Nazneen A, Nakashima Y, Razzaque MS, Nishino T, Furusu A, et al. Pathological influence of obesity on renal structural changes in chronic kidney disease. Clin Exp Nephrol. 2009;13:332-40.
15. Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant. 2010;25:1173-83.
16. Kataoka H, Ohara M, Honda K, Mochizuki T, Nitta K. Maximal glomerular diameter as a 10-year prognostic indicator for IgA nephropathy. Nephrol Dial Transplant. 2011;26:3937-43.
17. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76: 546-56.
18. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis. 2007;50:927-37.
19. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549-55.
20. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997;8:199-207.
21. Suzuki K, Honda K, Tanabe K, Toma H, Nihei H, Yamaguchi Y. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int. 2003;63:2286-94.
22. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129-35.
23. Blüher M. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol. 2010;21:38-43.
24. Wu Y, Liu Z, Xiang Z, Zeng C, Chen Z, Ma X, et al. Obesityrelated glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology. 2006;147:44-50.
25. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:1565-74.
26. Schrijvers BF, Rasch R, Tilton RG, Flyvbjerg A. High proteininduced glomerular hypertrophy is vascular endothelial growth factor-dependent. Kidney Int. 2002;61:1600-4.
27. Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I. Effects of antihypertensive drugs on glomerular morphology. Kidney Int. 1989;36:626-35.
28. Xu ZG, Yoo TH, Ryu DR, Cheon Park H, Ha SK, Han DS, et al. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Kidney Int. 2005;67:944-52.
29. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Tao TM, Oestreicher EM, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006;147:5363-73.